“If the AI runs on our own hardware, are we compliant?”
It’s one of the first questions practice owners ask about private AI. The honest answer: not on its own.
Any vendor who tells you otherwise is selling a shortcut.
Here’s what running AI locally does solve. Patient data doesn’t have to leave your building for your team to get the benefit of AI.
Here’s what it doesn’t solve. Compliance is still a team job:
→ Your compliance team decides which information the AI can use.
→ Your clinical leads check the outputs before anyone relies on them.
→ Your IT team sets the access controls and keeps the logs.
What changes is who is in control.
With cloud AI, you’re relying on someone else’s promise about your patients’ records. With AI on hardware you own, the rules are yours to set, check and change. If a model, a vendor or a regulation changes, you can adapt without handing your data to anyone.
After more than 30 years in healthtech and IT leadership, I think this is the conversation healthcare leaders should be having.
Not “Is AI safe?”
But “Who holds the keys?”
If you lead a clinic, hospital or health system: what’s the first question your team would ask before approving AI on patient data?
#PrivateAI
One of the challenges in drug discovery is deciding what deserves to move from computational research into the laboratory. Researchers can identify promising molecules, study biological pathways and generate large volumes of data, but each potential candidate still needs to be evaluated before significant resources are committed to experimental validation.
Ingenix, is approaching this problem with Thalamus Decision, a model designed to make structured decisions directly from biological data.
Thalamus Decision is not a replacement for laboratory validation or scientific judgement. Its potential value is in helping researchers prioritize experiments, narrow down candidates and make better use of limited research resources.
The next important test will be whether these results hold up across independent datasets and real drug discovery workflows. If they do, typed decision models could become a valuable part of how biological research moves from data analysis to experimental decisions.
China's growing use of American AI models to train domestic systems shows how difficult it is to contain the spread of AI capabilities through chip restrictions alone.
A Reuters investigation found that Chinese researchers and companies are using outputs from models such as OpenAI's GPT-4 and o1 to develop training datasets for smaller domestic models. This practice, known as knowledge distillation, allows a less capable model to learn from the answers, reasoning examples and task demonstrations produced by a more advanced one.
The industry will need to address the boundaries around model outputs and intellectual property without treating every form of knowledge transfer as misconduct. That distinction will matter as distillation becomes a more established part of AI development.
The introduction of AI into air traffic management creates a central dilemma: how to capture the speed and data processing benefits of automation without eroding the human oversight required to prevent catastrophic mistakes.
The FAA's new SMART system is an interesting case. Developed with Air Space Intelligence, it brings together 200 data streams, including weather forecasts, flight paths, traffic flow and controller staffing information, to help specialists anticipate congestion and identify better routes before problems arise.
In aviation, efficiency cannot come at the expense of safety. The measure of SMART's success will be if it consistently improves air traffic management while giving controllers reliable information they can trust.
Drug discovery and clinical development operate on very different timelines. Finding a promising molecule or identifying a potential treatment target is an important scientific achievement, even though it does not always establish that the treatment is safe and effective in people.
Before a potential treatment can reach patients, it must undergo preclinical testing, clinical trials and regulatory assessment. Each stage takes the time researchers need to establish that the treatment is safe, demonstrate that it works in humans and carefully evaluate its risks. These requirements cannot be bypassed by making computational research faster.
Computational tools could help researchers identify targets, analyze biological data, design molecules and improve parts of the development process, making important contributions to medicine.
However, we should be careful about turning faster discovery into promises of rapid cures. The measure of progress is if these advances produce treatments that are safe, effective and accessible to the people who need them.
Many forms of intellectual work depend on individual expertise, practice and time. Research, analysis and design are seen as crafts because producing good work required considerable human effort.
This economic model is now being challenged and the consequences will reach past productivity. Businesses are already rethinking staffing and professional services are facing new competition. People whose livelihoods depend on these activities will have to navigate a difficult transition.
We should be honest about the scale of this change while making sure that the gains do not accrue only to the owners of the technology. The people whose work is being transformed deserve a place in the conversation about how this new economy is organized.